Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Dogwood Therapeutics (DWTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stryker (SYK – Research Report) and Dogwood Therapeutics (DWTX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Stryker (SYK)
In a report released yesterday, Travis Steed from Bank of America Securities reiterated a Buy rating on Stryker, with a price target of $450.00. The company’s shares closed last Thursday at $354.30.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Stryker has an analyst consensus of Strong Buy, with a price target consensus of $428.21, a 19.8% upside from current levels. In a report issued on January 20, RBC Capital also maintained a Buy rating on the stock with a $435.00 price target.
See the top stocks recommended by analysts >>
Dogwood Therapeutics (DWTX)
H.C. Wainwright analyst Sean Lee CFA reiterated a Buy rating on Dogwood Therapeutics today and set a price target of $12.00. The company’s shares closed last Thursday at $2.90, close to its 52-week low of $1.62.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Dogwood Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.
